FINWIRES · TerminalLIVE
FINWIRES

$QGEN

5 stories mentioning QGEN

Every FINWIRES story that references QGEN, newest first.

Research

Research Alert: CFRA Keeps Hold Opinion On Shares Of Qiagen

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our target price of USD36, implying a 2026 P/E of 14.7x. This is at a discount to its historical average (20x-22x) to reflect the headwinds on its key growth contributor QuantiFERON, along with increased geopolitical and management uncertainties. This is partly cushioned by growth opportunities from other key products and improving shareholder returns. Qiagen published its full Q1 2026 results, which were in line with the preliminary results released in April. Q1 2026 net sales fell 1% CER dragged by QuantiFERON sales declining 5% CER due to reduced immigration testing demand in the U.S. and Middle East. In April, Qiagen downgraded 2026 guidance to 1%-2% CER sales growth from at least 5% and adjusted EPS to at least USD2.43 CER from USD2.50, and expect stronger trends in H2 supported by acquisition benefits and sequential QuantiFERON improvement. Our EPS estimates remained unchanged given the full Q1 results were in line with the preliminary figures.

$QGEN
Research

Research Alert: CFRA Keeps Hold Opinion On Shares Of Qiagen

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target price to USD36 from USD54, and we trim our EPS estimates to USD2.45 from USD2.53 for 2026 and to USD2.64 from USD2.74 for 2027 in light of the guidance cut. The target price implies a 2026 P/E of 14.7x, below its historical average of 20x-22x to reflect headwinds on its key growth contributor QuantiFERON. Qiagen's preliminary Q1 2026 net sales fell 1% CER, missing the company's outlook for at least 1% growth, dragged by QuantiFERON (-5% CER) due to reduced immigration testing demand in the U.S. and Middle East. Given the slow start to the year, Qiagen downgraded 2026 guidance to 1%-2% CER sales growth from at least 5% and adjusted EPS to at least USD2.43 CER from USD2.50. We view the sales miss and lowered outlook as disappointing. We still see QuantiFERON as a main growth contributor over the long term, thus monitoring progress in other patient testing groups remains key. Full Q1 results are scheduled for May 6, 2026.

$QGEN
Research

Baird Upgrades QIAGEN to Outperform From Neutral, Cuts Price Target to $43 From $53

QIAGEN (QGEN) has an average rating of overweight and mean price target of $47.69, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$QGEN
Research

Research Alert: Qiagen Cuts 2026 Outlook As Q1 Sales Miss On Weak Quantiferon Testing

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Qiagen's preliminary Q1 2026 net sales fell by 1% CER, missing the company's outlook for at least 1% growth, while reported sales grew 2% to USD492M, below consensus' USD501M. Preliminary adjusted EPS of USD0.54 was in line with the outlook, though overall results were dragged by QuantiFERON sales declining 5% CER due to reduced immigration testing demand in the U.S. and Middle East. The company downgraded 2026 guidance to 1%-2% CER sales growth (from at least 5% previously) and adjusted EPS to at least USD2.43 CER (from USD2.50 previously), expecting stronger trends in 2H, supported by acquisition benefits and sequential QuantiFERON improvement. We view the sales miss and lowered outlook as disappointing, but still see QuantiFERON as a main growth contributor, while the Parse acquisition should strengthen Qiagen's competitive position. That said, monitoring progress in other patient testing groups for QuantiFERON remains key. Full Q1 results are scheduled for May 6, 2026.

$QGEN
Research

Barclays Downgrades QIAGEN to Equalweight From Overweight, Adjusts Price Target to $44 From $48

QIAGEN (QGEN) has an average rating of overweight and mean price target of $54.01, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$QGEN